1 week Ago By Defense World Staff
Lisata Therapeutics, Inc. ( NASDAQ:LSTA – Get Free Report )’s share price rose 1.4% during mid-day trading on Wednesday .
The stock traded as high as $2.98 and last traded at $2.98.
Approximately 45,386 shares changed hands during mid-day trading, an increase of 215% from the average daily volume of 14,403 shares. The stock had previously closed at $2.94.
Wall Street Analysts Forecast Growth Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Lisata Therapeutics in a research note on Wednesday, December 11th. Get Our Latest Research Report on Lisata Therapeutics Lisata Therapeutics Price Performance Lisata Therapeutics ( NASDAQ:LSTA – Get Free Report ) last posted its earnings results on Tuesday, November 12th.
The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.
16. During the same period in the prior year, the company posted ($0.65) EPS.
Research analysts predict that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current year.
Institutional Investors Weigh In On Lisata Therapeutics A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its holdings in Lisata Therapeutics, Inc. ( NASDAQ:LSTA – Free Report ) by 48.
2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.
21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Institutional investors own 8.94% of the company’s stock.
About Lisata Therapeutics ( Get Free Report ) Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. See Also Five stocks we like better than Lisata Therapeutics NYSE Stocks Give Investors a Variety of Quality Options Work and Play: Investing in the Rise of Bleisure Travel What to Know About Investing in Penny Stocks Top Dividend Stocks to Buy Now as Bond Yields Could Lower What Do S&P 500 Stocks Tell Investors About the Market? SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
